A Research Study Looking Into the Effect of Semaglutide and NNC0480 0389 on Blood Levels of a Birth Control Pill in Woman After Menopause
ClinicalTrials.gov · NCT05153564 · Registry updated: 2023-11-13
- Condition / research focus
- Diabetes Mellitus, Type 2
- Sponsor
- Novo Nordisk A/S
- Countries with listed sites
- Germany
- Registry dates and results
- Start: 2021-12-13. Completion: 2022-09-01 (may be estimated). No results posted in this registry response.
Products and interventions (5)
Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.
- Semaglutide 1.34 mg/mL (drug)
- Semaglutide 3.0 mg/mL (drug)
- NNC0480-0389 10 mg/mL (drug)
- NNC0480-0389 30 mg/mL (drug)
- Microgynon® (drug)
Where the study takes place — 1 listed sites
Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.